natgillin/translations-raw huggingface dataset:
In chronic renal failure patients there may be a moderate dose-dependent rise in the platelet count within the normal range during treatment with NeoRecormon, especially after intravenous administration. 
Pri bolnikih s kronično ledvično boleznijo se lahko med zdravljenjem z zdravilom NeoRecormon, zlasti po intravenskem dajanju zmerno, odvisno od velikosti odmerka, poveča število trombocitov, ki pa ostane znotraj normalnega območja.
LABELS 5000 IU pre-filled syringe 
NALEPKE 5000 i.e. napolnjena injekcijska brizga
PHARMACEUTICAL FORM AND CONTENTS Lyophilisate and solvent for solution for injection 1 vial with lyophilisate (50,000 IU) for solution for injection, 1 ampoule with preserved solvent (10 ml), 1 reconstitution and withdrawal device, 1 disposable syringe (10 ml), 1 needle (21G2) 
1 viala z liofilizatom (50.000 i.e.) za raztopino za injiciranje, 1 ampula z vehiklom s konzervansoma (10 ml), 1 pripomoček za rekonstitucijo in odvzem, 1 injekcijska brizga (10 ml) za enkratno uporabo, 1 injekcijska igla (21G2)
NeoRecormon 2000 IU solution for injection in pre-filled syringe NeoRecormon 3000 IU solution for injection in pre-filled syringe NeoRecormon 4000 IU solution for injection in pre-filled syringe NeoRecormon 5000 IU solution for injection in pre-filled syringe NeoRecormon 6000 IU solution for injection in pre-filled syringe NeoRecormon 10,000 IU solution for injection in pre-filled syringe NeoRecormon 20,000 IU solution for injection in pre-filled syringe NeoRecormon 30,000 IU solution for injection in pre-filled syringe 
NeoRecormon 500 i.e. raztopina za injiciranje v napolnjeni injekcijski brizgi NeoRecormon 2000 i.e. raztopina za injiciranje v napolnjeni injekcijski brizgi NeoRecormon 3000 i.e. raztopina za injiciranje v napolnjeni injekcijski brizgi NeoRecormon 4000 i.e. raztopina za injiciranje v napolnjeni injekcijski brizgi NeoRecormon 5000 i.e. raztopina za injiciranje v napolnjeni injekcijski brizgi NeoRecormon 6000 i.e. raztopina za injiciranje v napolnjeni injekcijski brizgi NeoRecormon 10.000 i.e. raztopina za injiciranje v napolnjeni injekcijski brizgi NeoRecormon 20.000 i.e. raztopina za injiciranje v napolnjeni injekcijski brizgi NeoRecormon 30.000 i.e. raztopina za injiciranje v napolnjeni injekcijski brizgi
The single dose thus determined is administered twice weekly over 4 weeks. 
Tako določeni odmerek dajemo dvakrat na teden 4 tedne.
NeoRecormon in pre-filled syringe contains up to 0.3 mg phenylalanine/syringe as an excipient. 
Zdravilo NeoRecormon vsebuje kot pomožno snov do 0,3 mg fenilalanina v eni napolnjeni injekcijski brizgi.
Adverse reactions are listed in Table 3 below. 
Neželeni učinki so navedeni v spodnji preglednici 3.
Remove the needle and syringe from the injection port at the same angle as inserted. 
Odstranite injekcijsko brizgo z iglo iz injekcijskega dostopa pod enakim kotom, kot je bila vstavljena.
Pure red cell aplasia (PRCA) 
Čista aplazija rdečih krvnih celic
The dosage must be determined by the surgical team individually for each patient as a function of the required amount of pre-donated blood and the endogenous red cell reserve: The required amount of pre-donated blood depends on the anticipated blood loss, use of blood conserving procedures and the physical condition of the patient. 
Odmerjanje mora določiti kirurška ekipa za vsakega bolnika posamezno glede na potrebno količino vnaprej darovane krvi in endogeno rezervo rdečih krvničk:
Survival and tumour progression have been examined in five large controlled studies involving a total of 2833 patients, of which four were double-blind placebo-controlled studies and one was an openlabel study. 
V petih velikih, kontroliranih študijah, ki so skupaj zajele 2833 bolnikov, so preiskovali preživetje in napredovanje tumorja.
· Very rarely (may affect up to 1 in 10,000 people), patient experienced flu-like symptoms, especially when they just started treatment. 
• Zelo redko (pojavijo se lahko pri največ 1 od 10.000 bolnikov) so se pri bolnikih pojavili gripi podobni simptomi, še posebno, če so z zdravljenjem komaj začeli.
Consult your healthcare provider if you require further information. 
Če potrebujete dodatna navodila, se posvetujte z zdravstvenim delavcem.
On those occasions where the patient's PCV allows blood donation, i.e. PCV ³ 33 %, NeoRecormon is administered at the end of blood donation. 
Ko je vrednost hematokrita tolikšna, da je možen odvzem krvi (≥ 33 %), dajemo zdravilo NeoRecormon ob koncu odvzema.
One ml solution for injection contains 13,333 IU epoetin beta. 
En ml raztopine za injiciranje vsebuje 13.333 i.e. epoetina beta.
The dosage may be increased every 4 weeks by 3 x 20 IU/kg and week if the increase of Hb is not adequate (< 0.25 g/dl per week). 
Kadar ne dosežemo ustreznega povečanja koncentracije hemoglobina (< 0,25 g/dl na teden), lahko odmerek vsake 4 tedne povečamo za 3 x 20 i.e./kg na teden.
Remove the needle and syringe from the injection site at the same angle as inserted. 
Odstranite iglo z injekcijsko brizgo z mesta injiciranja pod enakim kotom, kot je bila vstavljena.
INFORMATION IN BRAILLE neorecormon 2000 IU 
PODATKI V BRAILLOVI PISAVI neorecormon 2000 i.e.
In very rare cases, neutralising anti-erythropoietin antibodies with or without pure red cell aplasia (PRCA) occurred during rHuEPO therapy. 
V zelo redkih primerih so med zdravljenjem z rekombinantnim humanim eritropoetinom poročali o pojavu nevtralizirajočih protiteles proti epoetinu s čisto aplazijo rdečih krvnih celic (PRCA) ali brez nje.
Severe cutaneous adverse reactions (SCARs) including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), which can be life-threatening or fatal, have been reported in association with epoetin treatment (see section 4.8). 
V povezavi z zdravljenjem z epoetini so poročali o hudih kožnih neželenih učinkih (SCAR - severe cutaneous adverse reactions), vključno s Stevens-Johnsonovim sindromom (SJS) in toksično epidermalno nekrolizo (TEN), ki so lahko življenje ogrožajoči ali smrtni (glejte poglavje 4.8).
1 prefilled syringe with one needle (30G1/2) or 6 pre-filled syringes with 6 needles (30G1/2). 
1 napolnjena injekcijska brizga z eno iglo (30G1/2) ali 6 napolnjenih injekcijskih brizg s 6 iglami (30G1/2).
If you have high or rising potassium levels your doctor may reconsider your treatment · your blood platelet count. 
Če bodo koncentracije kalija previsoke ali bodo naraščale, bo zdravnik ponovno pretehtal vaše zdravljenje;
L-Threonine, 
L-izolevcin, L-treonin,
· Very rarely (may affect up to 1 in 10,000 people) people experienced flu-like symptoms, especially when they just started treatment. 
• Zelo redko (pojavijo se lahko pri največ 1 od 10.000 bolnikov) so se pri bolnikih pojavil gripi podobni simptomi, še posebno, če so z zdravljenjem komaj začeli.
NeoRecormon 500 IU 
NeoRecormon 500 i.e.
What NeoRecormon contains 
Kaj vsebuje zdravilo NeoRecormon
·Do not fan or blow on the cleaned area. 
• Na očiščeno površino ne pihajte.
13 Hold the syringe with the needle pointing up. 
13 Držite injekcijsko brizgo z iglo, obrnjeno navzgor.
ESAs are not indicated for use in this patient population. 
Zdravil za stimulacijo eritropoeze pri tej skupini bolnikov ne smemo uporabljati.
MINIMUM PARTICULARS TO APPEAR ON THE OUTER PACKAGING OUTER CARTON 
PODATKI, KI MORAJO BITI NAJMANJ NAVEDENI NA ZUNANJI OVOJNINI ZUNANJA OVOJNINA
· Keep your unused syringe(s) in the original carton and store in a refrigerator at 2˚C to 8˚C. 
• Neuporabljene injekcijske brizge shranjujte v originalni ovojnini v hladilniku pri temperaturi med
Roche Registration GmbH Emil-Barell-Strasse 1 79639 Grenzach-Wyhlen Germany 
Emil-Barell-Strasse 1 79639 Grenzach-Wyhlen
This NeoRecormon presentation contains white lyophilisate and solvent. 
Ta oblika zdravila NeoRecormon vsebuje bel liofilizat in vehikel.
NeoRecormon 30,000 IU 1 prefilled syringe with one needle (27G1/2) or 4 pre-filled syringes with 4 needles (27G1/2). 
NeoRecormon 30.000 i.e. raztopina za injiciranje v napolnjeni injekcijski brizgi 1 napolnjena injekcijska brizga z eno injekcijsko iglo (27G1/2) ali 4 napolnjene injekcijske brizge s 4 injekcijskimi iglami (27G1/2).
Severe cutaneous adverse reactions (SCARs) including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), which can be life-threatening or fatal, have been reported in association with epoetin treatment (see section 4.4) 
V povezavi z zdravljenjem z epoetini so poročali o hudih kožnih neželenih učinkih (SCAR), vključno s Stevens-Johnsonovim sindromom (SJS) in toksično epidermalno nekrolizo (TEN), ki so lahko življenje ogrožajoči ali smrtni (glejte poglavje 4.4).
In isolated cases, neutralising anti erythropoietin antibody-mediated pure red cell aplasia (PRCA) associated with NeoRecormon therapy has been reported. 
Pri zdravljenju z zdravilom NeoRecormon so poročali o posameznih primerih čiste aplazije rdečih krvnih celic (PRCA - pure red cell aplasia), posredovane z nevtralizirajočimi protitelesi proti eritropoetinu.
6 Attach the needle to the syringe. 
6 Na injekcijsko brizgo namestite injekcijsko iglo.
One ml solution for injection contains 6667 IU epoetin beta. 
En ml raztopine za injiciranje vsebuje 6667 i.e. epoetina beta.
NeoRecormon 2000 IU, NeoRecormon 3000 IU, NeoRecormon 4000 IU, NeoRecormon 5000 IU, NeoRecormon 6000 IU, NeoRecormon 10,000 IU and NeoRecormon 20,000 IU solution for injection in pre-filled syringe 
NeoRecormon 2000 i.e., NeoRecormon 3000 i.e., NeoRecormon 4000 i.e., NeoRecormon 5000 i.e., NeoRecormon 6000 i.e., NeoRecormon 10.000 i.e. in NeoRecormon 20.000 i.e. raztopina za injiciranje v napolnjeni injekcijski brizgi
PHARMACEUTICAL FORM Lyophilisate and solvent for solution for injection. 
FARMACEVTSKA OBLIKA Liofilizat in vehikel za raztopino za injiciranje.
4 Inspect the syringe and needle closely · Check the syringe and needle for any damage. 
4 Injekcijsko brizgo in iglo pozorno preglejte
One ml solution for injection contains 16,667 IU epoetin beta. 
En ml raztopine za injiciranje vsebuje 16.667 i.e. epoetina beta.
NeoRecormon contains phenylalanine and sodium This medicine contains phenylalanine. 
Zdravilo NeoRecormon vsebuje fenilalanin in natrij.
· Do not recap the injection needle with the cap. · Do not throw away (dispose of) the syringe in your household trash. 
• Ne mecite (odstranjujte) injekcijske brizge med gospodinjske odpadke.
· Instructions for Use and a package leaflet. 
• navodila za dajanje zdravila in navodilo za uporabo
NeoRecormon Multidose contains up to 5.0 mg phenylalanine/vial as an excipient. 
Zdravilo NeoRecormon večodmerna raztopina za injiciranje vsebuje kot pomožno snov do 5,0 mg fenilalanina v eni viali.
For use of NeoRecormon in an autologous predonation programme, the official guidelines on principles of blood donation must be considered, in particular: - only patients with a PCV ³ 33 % (haemoglobin ³ 11 g/dl [6.83 mmol/l]) should donate; - special care should be taken with patients below 50 kg weight; - the single volume drawn should not exceed approx. 12 % of the patient's estimated blood volume. 
Kadar predpišemo zdravilo NeoRecormon v sklopu programa avtolognega darovanja krvi, moramo ravnati po uradnih smernicah o načelih darovanja krvi, zlasti naslednjih: - darovalci so lahko samo osebe s hematokritom ≥ 33 % in hemoglobinom ≥ 11 g/dl
Serum potassium and phosphate levels should be monitored regularly during therapy with NeoRecormon. 
Med zdravljenjem z zdravilom NeoRecormon moramo redno določati serumske koncentracije kalija in fosfata.
INFORMATION IN BRAILLE neorecormon 20.000 IU 
PODATKI V BRAILLOVI PISAVI neorecormon 20.000 i.e.
In the case of subcutaneous administration, the weekly dose can be given as one injection per week or in divided doses three or seven times per week. 
Pri subkutanem dajanju lahko tedenski odmerek damo kot eno injekcijo na teden ali razdeljenega na več odmerkov tri ali sedemkrat na teden.
Reconst. 
uporaba.
Additional side effects in adults receiving chemotherapy for cancer · Increase in blood pressure and headache may occasionally occur. 
• Zvišanje krvnega tlaka in glavobol se lahko pojavita občasno.
Meta-analyses also indicate consistently a significantly increased relative risk of thromboembolic events in cancer patients receiving recombinant human erythropoietin (see section 
Meta analize so pri bolnikih z rakom, ki prejemajo rekombinantni humani eritropetin, pokazale značilno povečano relativno tveganje za trombembolične dogodke (glejte poglavje 4.4).
NeoRecormon contains phenylalanine, benzyl alcohol and sodium This medicine contains phenylalanine. 
Zdravilo NeoRecormon vsebuje fenilalanin, benzilalhokol in natrij.
· Contact your healthcare professional if you have any questions. 
• Če imate kakršnakoli vprašanja, se obrnite na zdravstvenega delavca.
If the haemoglobin level continues to increase, therapy should be interrupted until the hemoglobin level begins to decrease, at which point therapy should be restarted at a dose approximately 25% below the previously administered dose. 
Če se koncentracija hemoglobina še vedno povečuje, zdravljenje prekinite, dokler koncentracija hemoglobina ne začne padati.
Adverse reactions attributed to the treatment with NeoRecormon in controlled clinical trials in CKD patients System organ class 
Preglednica 1: Neželeni učinki, povezani z zdravljenjem z zdravilom NeoRecormon, v nadzorovanih kliničnih preskušanjih pri bolnikih s kronično ledvično boleznijo Organski sistem
If you are a patient with chronic kidney disease, and particularly if you do not respond properly to NeoRecormon, your doctor will check your dose of NeoRecormon because repeatedly increasing your dose of NeoRecormon if you are not responding to treatment may increase the risk of having a problem of the heart or the blood vessels and could increase risk of myocardial infarction, stroke and death. 
Večkratno povečanje odmerka zdravila NeoRecormon lahko namreč v primeru, da se ne odzivate na zdravljenje, poveča tveganje za težave s srcem ali ožiljem, povečalo pa bi se lahko tudi tveganje za srčni infarkt, možgansko kap in smrt.
One ml solution for injection contains 20,000 IU epoetin beta. 
En ml raztopine za injiciranje vsebuje 20.000 i.e. epoetina beta.
Form a skin fold by pinching the skin between thumb and forefinger. 
S palcem in kazalcem napravite kožno gubo.
Misuse by healthy persons may lead to an excessive increase in packed cell volume. 
Pri zdravih osebah lahko nepravilna uporaba zdravila čezmerno poveča hematokrit, kar lahko povzroči življenjsko nevarne zaplete kardiovaskularnega sistema.
NeoRecormon Multidose is supplied as a lyophilisate for solution for injection in vials. 
Zdravilo NeoRecormon za večodmerno raztopino za injiciranje vsebuje liofilizat za raztopino za injiciranje v viali.
Adverse reactions attributed to the treatment with NeoRecormon in controlled clinical trials in patients in an autologous blood predonation programme System organ class 
Bolezni živčevja glavobol pogosti Preglednica 3: Neželeni učinki, povezani z zdravljenjem z zdravilom NeoRecormon, v nadzorovanih kliničnih preskušanjih pri bolnikih, ki sodelujejo v programu avtolognega darovanja krvi Organski sistem
Adverse reactions attributed to the treatment with NeoRecormon in controlled clinical trials in cancer patients System organ class 
Preglednica 2: Neželeni učinki, povezani z zdravljenjem z zdravilom NeoRecormon, v nadzorovanih kliničnih preskušanjih pri bolnikih z rakom
NAME OF THE MEDICINAL PRODUCT NeoRecormon Multidose 50,000 IU lyophilisate and solvent for solution for injection 
IME ZDRAVILA NeoRecormon 50.000 i.e. liofilizat in vehikel za večodmerno raztopino za injiciranje
Clean the skin at the site of injection using an alcohol wipe. 
Mesto injiciranja na koži očistite z alkoholom.
One ml solution for injection contains 1667 IU epoetin beta. 
En ml raztopine za injiciranje vsebuje 1667 i.e. epoetina beta.
Manufacturer 
uporaba
· Treating anaemia with related symptoms in adult cancer patients receiving chemotherapy · Treating people donating their own blood before surgery. 
• zdravljenje bolnikov, ki pred operacijo darujejo kri.
1 prefilled syringe with one needle (27G1/2) or 4 pre-filled syringes with 4 needles (27G1/2). 
1 napolnjena injekcijska brizga z eno iglo (27G1/2) ali 4 napolnjene injekcijske brizge s 4 iglami (27G1/2).
Use disposable sterile syringes and needles for each dose 
Za preprečitev navzkrižne okužbe je treba za vsako dajanje zdravila aseptično uporabljati sterilne brizge in igle za enkratno uporabo.
You can press a dry sterile pad over the injection site. 
Nanj lahko pritisnete suho sterilno blazinico.
This medicinal product contains less than 1 mmol sodium (23 mg) per dose, i.e. essentially “sodiumfree”. 
To zdravilo vsebuje manj kot 1 mmol natrija (23 mg) na odmerek, kar v bistvu pomeni ‘brez natrija'.
STATEMENT OF ACTIVE SUBSTANCE(S) 1 vial contains 50,000 IU epoetin beta. 
NAVEDBA ENE ALI VEČ ZDRAVILNIH UČINKOVIN 1 viala vsebuje 50.000 i.e. epoetina beta.
If you think you have missed an injection, or been injected too little, talk to your doctor. 
Če ste pozabili uporabiti zdravilo NeoRecormon Če menite, da ste izpustili injekcijo ali so vam injicirali premajhen odmerek, se posvetujte z zdravnikom.
· Keep the vials in the outer carton in order to protect from light. 
• Viale shranjujte v zunanji ovojnini za zagotovitev zaščite pred svetlobo.
Medicinal product contains phenylalanine and sodium and solvent contains benzyl alcohol, see leaflet for further information. 
Zdravilo vsebuje fenilalanin in natrij, vehikel pa benzilalkohol.
Serious skin reaction including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) have been reported in association with epoetin treatment. 
V povezavi z zdravljenjem z epoetini so poročali o hudih kožnih reakcijah, vključno s StevensJohnsonovim sindromom (SJS) in toksično epidermalno nekrolizo (TEN).
L-Glutamic acid, 
L-glutaminska kislina, L-fenilalanin,
· If you get any side effects, talk to your doctor or pharmacist. 
• Če opazite kateri koli neželeni učinek se posvetujte z zdravnikom ali farmacevtom.
· Pure red cell aplasia (PRCA) caused by neutralising antibodies has been observed during erythropoietin therapy, including in isolated cases during therapy with NeoRecormon. 
• Med zdravljenjem z eritropoetinom, vključno v posameznih primerih med zdravljenjem z zdravilom NeoRecormon, je bila opažena čista aplazija rdečih krvnih celic (PRCA - pure red cell aplasia), ki jo povzročajo nevtralizirajoča protitelesa.
Do not use the syringe if you have dropped the syringe or if any part of the syringe appears to be damaged. 
Injekcijske brizge ne uporabljajte, če vam je padla na tla ali če je katerikoli del brizge videti poškodovan.
· if you have blood pressure problems that cannot be controlled · if you are donating your own blood before surgery, and: · you had a heart attack or stroke in the month before your treatment · you have unstable angina pectoris - new or increasing chest pain · you are at risk of blood clots in the veins (deep venous thrombosis) - for example, if you have had clots before. 
• če pri vas obstaja tveganje za nastanek krvnih strdkov v venah (globoka venska tromboza)na primer, če ste imeli krvne strdke že v preteklosti;
The solution is administered subcutaneously at a dose of 3 x 250 IU/kg b.w. 
Raztopino dajemo subkutano v odmerku 3 x 250 i.e./kg telesne mase na teden.
If signs and symptoms suggestive of these reactions appear, NeoRecormon should be withdrawn immediately and an alternative treatement considered.If the patient has developed a severe cutaneous skin reaction such as SJS orTEN due to the use of NeoRecormon, treatment with ESA must not be restarted in this patient at any time. 
Če se pojavijo znaki in simptomi, ki kažejo na te reakcije, je treba zdravljenje z zdravilom NeoRecormon takoj prekiniti in razmisliti o drugi vrsti zdravljenja.
NeoRecormon Multidose 50,000 IU lyophilisate and solvent for solution for injection Epoetin beta 
NeoRecormon 50.000 i.e. liofilizat in vehikel za večodmerno raztopino za injiciranje epoetin beta
Sodium chloride, Polysorbate 20, Sodium dihydrogen phosphate, Disodium hydrogen phosphate, Calcium chloride, Glycine, 
sečnina, natrijev klorid, polisorbat 20, natrijev dihidrogenfosfat, natrijev hidrogenfosfat, kalcijev klorid,
One ml of reconstituted solution contains 5000 IU epoetin beta. 
En ml pripravljene raztopine vsebuje 5000 i.e. epoetina beta.
These antibodies have been shown to cross-react with all erythropoietic proteins, and patients suspected or confirmed to have neutralising antibodies to erythropoietin should not be switched to NeoRecormon (see section 4.8). 
Bolnikov, za katere sumimo ali za katere je potrjeno, da imajo nevtralizirajoča protitelesa proti eritropoetinu, ne smemo začeti zdraviti z zdravilom NeoRecormon (glejte poglavje 4.8).
1 prefilled syringe with one needle (27G1/2) or 6 pre-filled syringes with 6 needles (27G1/2). 
1 napolnjena injekcijska brizga z eno iglo (27G1/2) ali 6 napolnjenih injekcijskih brizg s 6 iglami (27G1/2).
One ml solution for injection contains 10,000 IU epoetin beta. 
En ml raztopine za injiciranje vsebuje 10.000 i.e. epoetina beta.
In most cases, a fall in serum ferritin values simultaneous with a rise in packed cell volume is observed (see section 4.4). 
Pri večini bolnikov spremlja povečanje hematokrita padec feritina v serumu (glejte poglavje 4.4).
· Keep this medicine out of the sight and reach of children. 
• Zdravilo shranjujte nedosegljivo otrokom!
NeoRecormon Multidose 50,000 IU 5000 IU/ ml 
neorecormon 50.000 i.e.
Remove the cap from the syringe. 
Odstranite pokrovček z brizge.
6 pre-filled syringes (0.3 ml) and 6 needles (30G1/2) 
6 napolnjenih injekcijskih brizg (0,3 ml) in 6 injekcijskih igel (30G1/2)
NeoRecormon 5000 IU solution for injection in pre-filled syringe One pre-filled syringe with 0.3 ml solution for injection contains 5000 international units (IU) corresponding to 41.5 micrograms epoetin beta* (recombinant human erythropoietin). 
NeoRecormon 5000 i.e. raztopina za injiciranje v napolnjeni injekcijski brizgi Ena napolnjena injekcijska brizga z 0,3 ml raztopine za injiciranje vsebuje 5000 mednarodnih enot (i.e.), kar ustreza 41,5 mikrogramom epoetina beta* (rekombinantni humani eritropoetin).
Meta-analysis of overall survival data produced a hazard ratio point estimate of 1.06 in favour of controls (95% CI: 1.00, 1.12; 53 trials and 13,933 patients) and for cancer patients receiving chemotherapy, the overall survival hazard ratio was 1.04 (95% CI: 0.97, 1.11; 38 trials and 10,441 patients). 
Meta analiza podatkov o celokupnem preživetju je podala oceno razmerja ogroženosti 1,06 v dobro kontrolne skupine (95-% interval zaupanja: 1,00, 1,12; 53 preskušanj in 13.933 bolnikov).
INFORMATION IN BRAILLE neorecormon 30.000 IU 
PODATKI V BRAILLOVI PISAVI neorecormon 30.000 i.e.
NeoRecormon Multidose is a lyophilisate and solvent for solution for injection. 
Večodmerno zdravilo NeoRecormon je na voljo kot liofilizat in vehikel za raztopino za injiciranje.
If you think you have been injected more NeoRecormon than you should, contact your doctor. 
Če so vam injicirali prevelik odmerek zdravila NeoRecormon Če mislite, da so vam injicirali več zdravila NeoRecormon, kot bi smeli, obvestite zdravnika.
· Do not hold the plunger while you remove the needle cap. · Do not touch the needle after removing the needle cap. · Do not re-cap the needle. 
• Ko odstranite pokrovček igle, se igle ne dotikajte.
· 1 dry sterile pad. 
• 1 alkoholni zloženec • 1 suha sterilna blazinica
INFORMATION IN BRAILLE neorecormon 3000 IU 
PODATKI V BRAILLOVI PISAVI neorecormon 3000 i.e.
How to store NeoRecormon · Keep this medicine out of the sight and reach of children. 
Kako uporabljati zdravilo NeoRecormon Pri uporabi tega zdravila natančno upoštevajte navodila zdravnika.
NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION NeoRecormon 2000 IU injection epoetin beta 
IME ZDRAVILA IN POT(I) UPORABE NeoRecormon 2000 i.e. injekcija epoetin beta i.v./s.c.
Vascular disorders 
Organski sistem
An increased 3H-thymidine incorporation in the erythroid nucleated spleen cells has been found in vitro (mouse spleen cell culture) after incubation with epoetin beta. 
V in vitro pogojih (celična kultura mišje vranice) so ugotovili povečan obseg vgrajevanja